Zevra Therapeutics, Inc. ZVRA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $36.22M+77.5% | $34.13M+183% | $26.06M+605% | $25.88M+482% | $20.4M+496% | ||
| $1.9M+41.0% | $1.52M+11.3% | $1.24M-46.2% | $12.38M+246% | $1.35M+669% | ||
| $34.32M+80.1% | $32.61M+205% | $24.83M+1,683% | $13.5M+1,441% | $19.06M+486% | ||
| 94.8%+1.4pp | 95.5%+6.9pp | 95.2%+57.6pp | 52.2%+32.5pp | 93.4%-1.5pp | ||
| $4.39M+34.8% | $2.62M-68.6% | $3.43M-68.6% | $3.43M-67.4% | $3.26M-73.5% | ||
| $20.78M+6.3% | $20.35M+26.2% | $16.94M+4.5% | $20.78M+64.9% | $19.55M+96.8% | ||
| $316K-80.4% | $316K-80.4% | $315K-79.6% | $1.62M+4.5% | $1.62M+5.7% | ||
| $25.18M+10.4% | $22.97M-6.1% | $20.37M-25.0% | $24.22M+4.7% | $22.8M+2.7% | ||
| $52.15M+1,073% | —— | $4.14M+115% | -$71.04M-199% | -$5.36M+73.8% | ||
| 144%+170pp | —— | 15.9%+755pp | -274.5%+260pp | -26.3%+572pp | ||
| $1.71M-13.1% | $1.95M-11.2% | $2.05M-11.3% | $2.01M-4.8% | $1.97M+168% | ||
| -$7.34M-313% | $3.35M+168% | -$5.12M+13.5% | $147.95M+3,655% | $3.45M-9.2% | ||
| -$2.76M— | —— | —— | —— | $0— | ||
| $43.31M— | $0— | $0— | $148.33M— | $0— | ||
| $44.8M+2,437% | $12.67M+162% | -$977K+97.1% | $76.91M+487% | -$1.92M+88.5% | ||
| $6.91M+485% | $501K-96.7% | -$433K— | $2.2M+3,041% | $1.18M+1,789% | ||
| $37.89M+1,323% | $12.17M+134% | -$544K+98.4% | $74.71M+475% | -$3.1M+81.4% | ||
| 104.6%+120pp | 35.6%+332pp | -2.1%+897pp | 288.7%+737pp | -15.2%+470pp | ||
| $0.60+1,100% | $0.19+128% | -$0.01+98.6% | $1.21+352% | -$0.06+85.7% | ||
| $0.62+1,133% | $0.20+129% | -$0.01+98.6% | $1.24+358% | -$0.06+85.0% | ||
| 60.2M+11.3% | 57.3M+23.8% | 56M+17.0% | 56.3M+34.4% | 54.1M— | ||
| 58.4M+8.0% | 55.3M+19.6% | 56M+17.0% | 54.8M+30.7% | 54.1M+29.5% | ||
| $316K-80.4% | $316K-80.4% | $315K-79.6% | $1.62M+4.5% | $1.62M+5.7% | ||
| -$968K+80.1% | -$3.56M— | $5.51M+16.0% | $747K+113% | -$4.87M— | ||
| $43.31M— | —— | —— | —— | $0— | ||
| $3.59M+561% | $1.71M— | $2.31M+120% | $2.38M+781% | $543K-41.6% | ||
| $4.39M+34.8% | $2.62M-68.6% | $3.43M-68.6% | $3.43M-67.4% | $3.26M-73.5% | ||
| -$7.22M— | —— | —— | —— | $0— | ||
| $52.15M+1,073% | $14.61M+195% | $4.14M+115% | -$71.04M-199% | -$5.36M+73.8% | ||
| $52.51M+1,514% | $14.98M+209% | $4.54M+118% | -$69.39M-212% | -$3.71M+80.4% | ||
| $52.51M+1,514% | $14.98M+209% | $4.54M+118% | -$69.39M-212% | -$3.71M+80.4% | ||
| 145%+163pp | 43.9%+158pp | 17.4%+713pp | -268.1%+232pp | -18.2%+534pp | ||
| $52.15M+1,073% | $14.61M+195% | $4.14M+115% | -$71.04M-199% | -$5.36M+73.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $122.3M in revenue over the trailing twelve months, up 201.3% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $124.2M in net income over the trailing twelve months, a 101.6% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 86.1% and operating margin is -103.9%, with a 101.6% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $1.99.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
